Novo Nordisk A/S buy gerihouse
Summary
This prediction ended on 17.01.13 with a price of €26.45. With a performance of 6.20%, the BUY prediction by gerihouse for Novo Nordisk A/S closed with a slight gain. gerihouse has 50% into this predictionNovo Nordisk is a Danish pharmaceutical company that specializes in diabetes care and research. It is considered to be one of the largest companies in the world that focus exclusively on diabetes management, with a product portfolio that ranges from insulin treatment to obesity management. The company is listed on the Copenhagen Stock Exchange and has gained global recognition for its commitment to sustainable business practices and its contribution to diabetes research and treatment. Novo Nordisk has a strong financial track record and has consistently delivered solid returns to investors over the years.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Novo Nordisk A/S | - | - | - | - |
| iShares Core DAX® | 0.051% | 5.593% | 14.403% | 19.767% |
| iShares Nasdaq 100 | 1.808% | 7.445% | 34.917% | 57.237% |
| iShares Nikkei 225® | 2.181% | 2.815% | 11.116% | 8.873% |
| iShares S&P 500 | 1.040% | 4.975% | 27.631% | 48.786% |
Comments by gerihouse for this prediction
In the thread Novo Nordisk A/S diskutieren
Luft geholt
Das beeindruckende Wachstum bei Umsatz und Gewinn schlägt sich auch im Aktienkurs von Novo Nordisk nieder. In den vergangenen 20 Jahren hat die Aktie im Schnitt rund 17 Prozent zugelegt. Der langfristige Aufwärtstrend von Novo Nordisk ist intakt. Zuletzt hat das Papier etwas Luft geholt, die letzten Tage ging es allerdings wieder aufwärts. Für Investoren stellt dies eine gute Einstiegsmöglichkeit dar.
Stopped prediction by gerihouse for Novo Nordisk A/S
Novo Nordisk A/S
07.03.23
07.03.24
08.03.24
Novo Nordisk A/S
20.01.22
20.01.23
02.01.23
Novo Nordisk A/S
08.07.21
08.07.22
15.11.21